Aromatase Acetylation Patterns and Altered Activity in Response to Sirtuin Inhibition
Authors:
- 1 October 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 16 (10) , 1530-1542
Abstract
Aromatase, a cytochrome P450 member, is a key enzyme involved in estrogen biosynthesis and is dysregulated in the majority of breast cancers. Studies have shown that lysine deacetylase inhibitors (KDI) decrease aromatase expression in cancer cells, yet many unknowns remain regarding the mechanism by which this occurs. However, advances have been made to clarify factors involved in the transcriptional regulation of the aromatase gene (CYP19A1). Yet, despite aromatase being a primary target for breast cancer therapy, its posttranslational regulation has been virtually unexplored. Acetylation is a posttranslational modification (PTM) known to alter the activity and stability of many oncoproteins, and given the role of KDIs in regulating aromatase expression, we postulate that aromatase acetylation acts as a novel posttranslational regulatory mechanism that impacts aromatase expression and/or activity in breast cancer. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis revealed that aromatase is basally acetylated on several lysine residues (108, 169, 242, 262, 334, 352, and 354) in MCF-7 cells, and treatment with a SIRT-1 inhibitor induced additional acetylation (376, 390, 440, and 448). These acetylated lysine residues are in regions critical for aromatase activity. Site-directed mutagenesis and overexpression studies demonstrated that K108R/Q or K440R/Q mutations significantly altered aromatase activity in breast cancer cells without altering its subcellular localization. Implications: These findings demonstrate a novel posttranslational regulation of aromatase and uncover novel anticancer effects of deacetylase inhibitors, thus providing new insight for ongoing development of deacetylase inhibitors as cancer therapeutics. Mol Cancer Res; 16(10); 1530–42. ©2018 AACR.Keywords
All Related Versions
Funding Information
- National Institutes of Health (CA155223)
This publication has 51 references indexed in Scilit:
- Aromatase, breast cancer and obesity: a complex interactionTrends in Endocrinology & Metabolism, 2012
- Estrogen-Related Receptor γ (ERRγ) Mediates Oxygen-Dependent Induction of Aromatase (CYP19) Gene Expression during Human Trophoblast DifferentiationMolecular Endocrinology, 2011
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Hypoxia Increases Sirtuin 1 Expression in a Hypoxia-inducible Factor-dependent MannerJournal of Biological Chemistry, 2011
- Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to LetrozoleCancer Research, 2011
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2010
- The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expressionProceedings of the National Academy of Sciences, 2010
- Sirtuin 1 Modulates Cellular Responses to Hypoxia by Deacetylating Hypoxia-Inducible Factor 1αMolecular Cell, 2010
- X-ray structure of human aromatase reveals an androgen-specific active siteThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Estrogen Carcinogenesis in Breast CancerNew England Journal of Medicine, 2006